Pharmaceuticals

Global Respiratory Biologics Industry Trends: Where the Market Is Headed by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Respiratory Biologics Market Size Likely To Evolve From 2025 Through 2034?

The market size for respiratory biologics has shown rapid expansion in recent years. It is anticipated to increase from $6.38 billion in 2024 to $7.41 billion in 2025, achieving a compound annual growth rate (CAGR) of 16.1%. This historical growth can be linked to factors including the increasing prevalence of respiratory diseases, the rising adoption of personalized medicine, growing healthcare expenditure globally, increasing awareness and diagnosis rates of respiratory conditions, and an expanding geriatric population with respiratory disorders.

The respiratory biologics market is anticipated to experience rapid expansion in the coming years. Its size is projected to reach $13.51 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 16.2%. This growth during the forecast period is attributable to factors such as the increasing prevalence of asthma and COPD, wider adoption of biologic therapies, higher spending on research and development, growing demand for non-invasive drug delivery, and the broadening of reimbursement policies. Major trends expected in the forecast period include the increased use of monoclonal antibodies for respiratory diseases, advancements in biologic drug formulations and delivery methods, new regulatory approvals, strategic collaborations and acquisitions among key industry players, and the integration of artificial intelligence in drug discovery and development processes.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

Which Drivers Are Shaping The Respiratory Biologics Industry’s Market Share?

The anticipated expansion of the respiratory biologics market going forward is directly linked to the increase in air pollution. Air pollution is characterized by the presence of detrimental substances, such as gases, particulate matter, and biological molecules, within the Earth’s atmosphere, which adversely affect both human health and the environment. This rise in atmospheric contamination is a consequence of escalating industrialization and urbanization, leading to increased emissions from factories, vehicles, and construction activities. Respiratory biologics play a crucial role in countering the health impacts of air pollution by offering targeted treatments that diminish inflammation and enhance lung function in individuals exposed to airborne pollutants. For instance, in January 2025, the Environmental Protection Agency, a US-based government agency, reported that the United States released over 66 million tons of pollutants into the atmosphere in 2023. Furthermore, in September 2022, the United Nations Environment Programme, a Kenya-based environmental authority, highlighted that air pollution contributes to 7 million early deaths annually, and 99% of the world’s population breathes dirty air. Hence, the increasing air pollution is a significant driver for the growth of the respiratory biologics market.

What Are The Primary Types Of Segments Analyzed In The Respiratory Biologics Market?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcuteneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegments:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

What Key Innovation Trends Are Fueling Advancements In The Respiratory Biologics Market?

Key companies in the respiratory biologics market are concentrating on developing advanced biologic therapies, such as targeted immune therapies for chronic respiratory diseases, with the goal of providing precise treatments that diminish inflammation and improve pulmonary function. Targeted immune therapies for chronic respiratory diseases are interventions designed to modulate the body’s immune system to reduce swelling and respiratory issues in long-standing lung conditions. For example, in September 2024, Sanofi S.A., a France-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who presented with an eosinophilic phenotype. This approval marked a significant milestone, making Dupixent the first biologic medicine authorized in the US for treating this specific group of COPD patients.

Who Are The Core Companies Influencing The Respiratory Biologics Market Landscape?

Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

Which Region Is Projected To Lead The Respiratory Biologics Market During The Forecast Period?

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Respiratory Biologics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

Browse Through More Reports Similar to the Global Respiratory Biologics Market 2025, By The Business Research Company

Respiratory Disease Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Pharmaceutical Drugs And Biologics Logistics Market 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-and-biologics-logistics-market

Anesthesia And Respiratory Devices Market 2025

https://www.thebusinessresearchcompany.com/report/anesthesia-and-respiratory-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795